A Phase 2, Open-Label, Fixed Dose Study to Evaluate the Use of Sodium Phenylbutyrate (ACER-001) in the Treatment of Pediatric and Adult Patients With MCAD Deficiency Caused by the Common ACADM c.985 A>G (K304E) Mutation
Latest Information Update: 02 Apr 2024
Price :
$35 *
At a glance
- Drugs Sodium phenylbutyrate (Primary)
- Indications Medium chain acyl CoA dehydrogenase deficiency
- Focus Adverse reactions
- 08 Jan 2024 Planned End Date changed from 30 Jun 2025 to 1 Dec 2025.
- 08 Jan 2024 Planned primary completion date changed from 31 Dec 2024 to 1 Jun 2025.
- 08 Jan 2024 Planned initiation date (estimated date of first participant enrollment) changed from 1 Dec 2023 to 1 Apr 2024.